Sigma 2 receptor (σ2R) is overexpressed in select
cancers
and is regarded as a biomarker for tumor proliferation. σ2R
ligands are emerging as promising theranostics for cancer and neurodegenerative
diseases. Herein, we describe the design and synthesis of a series
of novel quinolyl pyrazinamides as selective and potent σ2R
ligands that show sub-micromolar potency in pancreatic cancer cell
lines. Compounds 14 (JR1-157) and 17 (JR2-298)
bind σ2R with K
i of 47 and 10 nM,
respectively. Importantly, compound 14 has an oral bioavailability
of 60% and shows significant in vivo efficacy without obvious toxicity
in a syngeneic model of pancreatic cancer. The cytotoxicity of the
quinolyl pyrazinamides significantly enhanced in the presence of copper
and diminished in the presence of the copper-chelator tetrathiomolybdate.
In conclusion, compound 14 is water-soluble, metabolically
stable, orally active, and increases the expression of the autophagy
marker LC3B and warrants further development for the treatment of
pancreatic cancer.